Drug, bio-affecting and body treating compositions inventions 04/06

20060089297 - Sperm specific lysozyme-like proteins: The present invention is directed to a family of testis specific proteins (SLLPs) that share high sequence identity to lysozyme-C proteins. The application encompasses compositions comprising the SLLP proteins, antibodies specific for the SLLP polypeptides and the use of the SLLP polypeptides and antibodies directed to such peptides as contraceptive...

20060089300 - Macrocyclic peptides active against the hepatitis c virus: wherein R1 is (C1-8)alkyl, (C3-7)cycloalkyl, {(C1-6)alkyl-(C3-7)cycloalkyl} or Het, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O—(C1-6)alkyl, amido, amino or phenyl, or R1 is C6 or C10 aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C1-6)alkyl, O—(C1-6)alkyl, amido,...

20060089298 - Novel substances k01-b0171 and process for producing the same: The present invention is comprised of culturing a microorganism having ability to produce K01-B0171-B substance and/or K01-B0171-C substance in a medium, accumulating K01-B0171-B substance and/or K01-B0171-C substance in a culture fluid and isolating K01-B0171-B substance and/or, K01-B0171-C substance from the culture fluid. The obtained K01-B0171-B substance, K01-B0171-C substance or a...

20060089299 - Selective treatment of endothelial somatostatin receptors: The invention provides for the use of somatostatin receptor selective ligands (selective for SSTR1 or SSTR4) to treat human endothelial cells and to formulate medicaments for human use. The medicaments may for example be used to treat an angiogenic disease. In various embodiments, the angiogenic disease may for example be...

20060089301 - 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection: e

20060089303 - Cancer-testis antigens: Cancer-testis (CT) antigens have been identified by screening public databases for transcripts that are expressed in tumor tissues and a limited set of normal tissues, or by screening for genes that are expressed in cancer and testis tissues (but not other normal tissues). The invention relates to nucleic acids and...

20060089305 - Compositions and methods for activating toll-like receptor 4: Methods for activating Toll-like receptor 4 via cholesterol-dependent cytolysins isolated from a Gram-positive bacteria are provided. In addition compositions containing an isolated cholesterol-dependent cytolysin or a fragment thereof or a mimetic of the cytolysin or fragment thereof and methods for use of such composition in inhibiting binding and/or interaction of...

20060089302 - Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases: The invention relates to specific peptides derived from hsp70, and to pharmaceutical compositions comprising the same. The peptides and compositions of the invention are particularly suitable for the prevention or treatment of an autoimmune disease such as Type 1 Diabetes, Systemic Lupus Erithematosus, Multiple Sclerosis or Rheumatoid Arthritis. The invention...

20060089306 - New epilepsy mutations: An isolated nucleic acid molecule encoding a mutant alpha subunit of a mammalian voltage-gated sodium channel, wherein a mutation event selected from the group consisting of point mutations, deletions, insertions and rearrangements has occurred and said mutation event disrupts the functioning of an assembled sodium channel comprising this mutated subunit...

20060089304 - Treatment of psoriasis through down-regulation of the egf-receptor with topically-applied egf: From unrelated but similar fields it is deduced that certain forms of psoriasis can be effectively treated through topical application of EGF-containing formulations. This patent application summarizes the theoretical basis for this finding and requests protection for the idea, while clinical evaluation is in preparation....

20060089308 - Method of improving ovulation induction using an androgen such as dehydroepiandrosterone: A method of preconditioning ovulation induction in a human female comprises of administering an androgen, for example, DHEA, for at least about four consecutive months. DHEA may be administered along with high dose gonadotrophins in ovulation induction treatments. Moreover, DHEA may be administered with follicle stimulating hormone, human menopausal gonadotrophin,...

20060089307 - Peptides that bind to the heparin binding domian of vegf and vegfr-2: The present invention relates to new peptides for targeting that bind to the heparin binding domain of vascular endothelial growth factor and its receptor vascular endothelial growth factor receptor 2, VEGFR-2. The invention further relates to their use in therapeutically effective treatment as well as for diagnostic imaging techniques....

20060089309 - Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds: The present invention provides for a method for stimulating the proliferation of pluripotential stem cells in a mammal comprising administration of pregnancy related compounds more particularly human chorionic gonadotropin, leutenizing hormone or prolactin. The present invention further provides for a method of treatment of tissues or organs experiencing cellular damage,...

20060089310 - Treatment of infections and other disorders: Microbial infections including anthrax infection, and gastrointestinal disorders, are treated or prevented by administration of an actin-sequestering peptide including amino acid sequence LKKTET, such as Thymosin β4, an isoform of Thymosin β4, oxidized Thymosin β4, or Tβ4 sulfoxide....

20060089311 - Agonists and antagonists of ryzn for the treatment of metabolic disorders: The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to,...

20060089313 - Methods and compositions for ameliorating the undesirable effects of chemotherapy: In one aspect, the present invention provides chemoprotectant compositions that each comprise at least two of the chemoprotectants disclosed herein. The chemoprotectant compositions of the invention are useful, for example, for ameliorating at least one adverse effect of chemotherapy. In another aspect, the present invention provides methods of ameliorating at...

20060089312 - Protease inhibitors: The present invention relates to prodrugs of protease inhibitors, such as inhibitors of proteosome, DPOP IV, FAPα and the like. These “pro-inhibitors” are activated, i.e., cleaved by an “activated protease” to release an active inhibitor moiety in proximity to a “target protease”. The identity of activating protease and target protease...

20060089314 - Image heating apparatus and method for manufacturing image heating apparatus: An image heating apparatus includes a heating roller for heating an image on a recording material; a coil unit disposed in said heating roller and including a coil for induction heat generation in said heating roller; a supporting member for rotatably supporting said heating roller, wherein said supporting member including...

20060089315 - Granular pesticidal composition:

20060089316 - Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof: Disclosed are methods of using various compounds, which are known to bind to 3-deoxyglucosone (3DG) or precursors thereof, in order to reduce a susceptibility to tumor formation and/or to prevent or delay onset of tumor formation induced by 3DG and its precursors. Also disclosed is the reduction of 3DG levels...

20060089317 - Treatment of metastatic breast cancer with anthracyclines, and taxanes: An improved adjuvant treatment of metastatic breast cancer in which patients are administered an anthracycline chemotherapeutic agent and a taxane chemotherapeutic agent is provided in which a diphenyl compound which is a potent antagonist of histamine binding at the intracellular histamine receptor is initially administered prior to administration of the...

20060089318 - Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases: The present invention provides compounds having the formula: (I); Also provided are pro-drug compounds of the formula: (II); The invention also provides pharmaceutical compositions containing the above compounds, methods of using the above compounds as pharmaceuticals, and processes for preparing the above compounds. Methods for inhibiting an ADP-ribosyl transferase, ADP-ribosyl...

20060089319 - Method for treatment and prevention of bacterial vaginosis: Methods for treatment and prevention of bacterial vaginosis are described. In order to treat a patient diagnosed with bacterial vaginosis, an antibiotic is administered to the patient and all infected participant-partners. Bacterial vaginosis is prevented in a human patient planning to participate in activities in which the patient's vagina may...

20060089325 - Antisense modulation of ptp1b expression: Compositions and methods are provided for decreasing blood glucose levels in an animal or for preventing or delaying the onset of a rise in blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of PTP1B expression in combination with at least one glucose-lowering drug. The...

20060089322 - Antisense oligonucleotides for identifying drug targets and enhancing cancer therapies: The present invention provides antisense oligonucleotides useful for identifying drug targets for cancer therapies and for enhancing current cancer therapies. The oligonucleotides of the invention are complementary to thymidylate synthase mRNA and affect expression of at least one other gene. For the enhancement of cancer therapies, such antisense oligonucleotides can...

20060089321 - Cks1 inhibitors: Inhibitors of human Cks1 and human Skp2, including antisense oligonucleotides, methods, and compositions specific for human Cks1 and human Skp2, are provided. Methods of using the compositions for modulating Cks1 expression and Skp2 expression, and for regulating cell growth, particularly tumor cell growth, are also provided....

20060089326 - Immunostimulatory nucleic acid molecules: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed....

20060089320 - Modulation of type iiß phosphoinositide phosphate kinase: The invention provides methods for modulating type IIβ phosphoinisitide phosphate kinase (PIPKIIβ) activity for treating PIPKIIβ-associated disorders. The invention also provides methods of identifying candidate agents for treating PIPKIIβ-associated disorders....

20060089323 - Rnai modulation of rsv, piv and other respiratory viruses and uses thereof: The present invention is based on the in vivo demonstration that RSV and PIV can be inhibited through intranasal administration of RNAi agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated...

20060089324 - Rnai modulation of rsv, piv and other respiratory viruses and uses thereof: The present invention is based on the in vivo demonstration that RSV and PIV can be inhibited through intranasal administration of RNAi agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated...

20060089327 - Combinations comprising epothilones and anti-metabolites: Disclosed is a combination which comprises (a) an antineoplastic antimetabolite and (b) an epothilone derivative of formula (I), wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R′ is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino, aminomethyl or methylthio, and Z...

20060089329 - Ready-to-use gemcitabine solution concentrates: Provided are ready-to-use pharmaceutical compositions in the form of gemcitabine solution concentrates....

20060089328 - Ready-to-use gemcitabine solutions: Provided are ready-to-use pharmaceutical compositions in the form of gemcitabine solutions....

20060089330 - Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans: One aspect of the present invention relates to solution-phase approaches to GPI synthesis. Another aspect of the present invention relates to key building blocks, and syntheses thereof, useful for GPI assembly. Yet another aspect of the invention relates to an automated method for the synthesis of GPIs and fragments thereof....

20060089331 - Methods and compositions for reducing toxicity of a pharmaceutical compound: The present disclosure is related to clear aqueous solutions of one or more bile acids and either an aqueous soluble starch conversion product or a non-starch polysaccharide. Solutions of the disclosure may be administered to a subject in conjunction with a pharmaceutical compound having one or more toxic effects. In...

20060089332 - Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents: e

20060089333 - Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents: wherein A+ represents an ammonium species selected from the protonated (conjugate acid) or quaternary forms of aliphatic amines and aromatic amines, including basic amino acids, heterocyclic amines, substituted and unsubstituted pyridines, guanidines and amidines; and X and Y independently represent leaving groups. Also disclosed herein are methods for making such...

20060089334 - Aminoalkylphosphonates and related compounds as edg receptor agonists: The present invention encompasses compounds or Formula (I): as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included....

20060089335 - Compositions and methods for enhancing cognitive function and synaptic plasticity: The present invention provides compositions and methods for enhancing cognitive function and synaptic plasticity. According to the method, Ca++ influx into excitatory neurons (nerve cells) is decreased by treatment with a number of different agents including divalent cations (e.g., Mg++), GABAB agonists, GABAA agonists, calcium channel blockers, and/or compounds that...

20060089336 - 4-dedimethylamino tetracycline compounds: The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux...

20060089338 - Dosage form for hormonal contraception: A dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for daily, oral administration, where the hormone-containing daily units each contain at most the minimum effective daily amount of folic acid for women and the hormone-free daily units...

20060089337 - Estrogen replacement regimen: The present invention provides an improved method to deliver estrogen to menopausal women comprising administering ultra-low dose estradiol alternating with standard-dose estradiol....

20060089339 - Method of improving cumulative embryo score and quantity of fertilized ooytes, increasing euploidy rate and of normalizing ovarian function using an androgen such as dehydroepiandrosterone: A method of improving cumulative embryo score may comprise administering an androgen to a human female, for example, DHEA, for at least about four consecutive months followed by harvesting and fertilizing oocytes and forming embryos. Between about 50 mg and about 100 mg of DHEA may be administered to a...

20060089340 - Novel steroids and steroid mimetics; method for their production; and use thereof: The invention relates to the production and use of novel 14β-alkyl-18-norsteroids, 8α,14β-dialkyl-18-norsteroids, spiro[cyclopentano-perhydronaphthalin]-3,1′-pentanes or hexanes in addition to 14β-fluoro-15β,17β-dihydroxy-steroids, by reacting 17-hydroxy-14,15-epoxi-steroids with water-free acids or Lewis acids and followed by derivatisation. The resulting compounds can be used as intermediate products for or as medicaments in human and veterinary medicine,...

20060089341 - Protein-bound derivatives of platinum complexes containing cyclobutane1,1-dicarboxyllate ligands: The invention concerns low-molecular platinum complexes containing cyclobutane-1,1-dicarboxylate ligands that contain a protein-binding group....

20060089342 - Topical anti-microbial compositions: Disclosed are topical compositions for the treatment of microbial infections on the skin or scalp which include a polyvalent metal salt of pyrithione and include a metal ion source. Also disclosed are methods for treating microbial infections of the skin or scalp using such compositions....

20060089343 - Superoxide dismutase mimics for the treatment of ocular disorders and diseases: The use of SOD mimics, particularly Mn(III) porphyrin complexes, for the treatment of AMD, DR, and retinal edema is disclosed....

20060089344 - Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics: in which A=N or CR2; R2═H, F, OH, CN, CF3, C1-6-alkyl, C12-6-alkoxy; n=2 or 3 and m=2 when A=N; n=1, 2 or 3 and m=1 or 2 when A=CR2; B=covalent bond or C1-8-alkylene; R1=optionally substituted heteroaryl; R3═CHR4CONHR5; R4═H or C1-6-alkyl; R5═H, C1-6-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-C6-alkylene; in the form of a base,...

20060089345 - Indole derivatives, method for preparating same and pharmaceutical compositions containing same:

20060089346 - Novel lactams and uses thereof: Compounds having the formula (1) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid B protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit γ secretase and thereby inhibit the production of amyloid β protein, thereby acting to...

20060089347 - Substituted azepines as histamine h3 receptor antagonists, preparation and therapeutic uses: The present invention discloses novel substituted azepine compounds of Formula (I) or pharmaceutically acceptable salts thereof which have selective histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such azepines as well as methods of using them to...

20060089348 - Substituted quinoline-4-carboxylic hydrazides as nk-2/nk-3 receptor ligands: The present invention discloses a compound of formula (I): wherein: R1 is an aryl or heteroaryl ring; R2 is hydroxy, C1-6 alkoxy, C1-6 alkyl, amino, NR′R″ or C1-6 alkyl-NR′R″ where R′ and R″ are independently chosen from hydrogen and C1-4 alkyl and where R′ and R″, together with the nitrogen...

20060089349 - 11beta-hydroxysteroid dehydrogenase type 1 active compounds: A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment...

20060089350 - Methods and compositions for the treatment of neuropsychiatric disorders: The present invention relates to methods and compositions for treating neuropathic pain and neuropsychiatric disorders by administering agents that are effective in reducing the effective amount, inactivating, and/or inhibiting the activity of a Na+—K+-2Cl− (NKCC) cotransporter. In certain embodiments, the Na+—K+-2Cl− co-transporter is NKCC1....

20060089351 - Neuropeptide receptor modulators: e

20060089352 - Substituted thiazines as material protecting agents: The invention relates to novel thiazines of formula (I), wherein the substituents R1 to R7 have the designation cited in the description, and to the metallic salts and acid addition compounds thereof. Said novel thiazines have an excellent capacity for protecting technical materials from being infected by micro-organisms....

20060089353 - Indole derivative compounds and drugs containing the compounds as the active ingredient: (wherein the symbols in the formula are as mentioned in the specification) and a salt thereof Since the compounds represented by formula (I) binds to PGD2 receptors and shows antagonistic activity, they are believed to be useful for prevention and/or treatment of diseases such as allergic disease (such as allergic...

20060089354 - Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators: Acid-substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for...

20060089355 - Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides: Disclosed are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting de-position of A beta peptide in a mammal, by use of compounds of formula (I) wherein the variables R1, R2, R3, R4, R5, X1, and X2 are defined herein....

20060089356 - Substituted imidazoles as cannabinoid receptor modulators: The use of compounds of the present invention as antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor particularly in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor. The invention is concerned with the use of these novel compounds to selectively antagonize the Cannabinoid-1 (CB1)...

20060089357 - Novel compounds and compositions as cathepsin inhibitors: The present invention relates to novel cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making....

20060089358 - Pyrrolotriazine compounds: and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth...

20060089359 - Phthalazinone derivatives: d

20060089361 - Methods for treating retinal diseases: wherein the 2-imidazolin-2-ylamino group is in either the 5- or 6-position of the quinoxaline nucleus; x, y and z are in any of the remaining 5-, 6-, 7- or 8-positions and are selected from hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; and R is an optional substituent in either...

20060089360 - Vanilloid receptor ligands and their use in treatments: Substituted nitrogen-containing heterocycles and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with...

20060089362 - Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same: A compound represented by the formula (Ia) (wherein R1a, R2a, and R3 to R5 are the same as defined in the description), a prodrug thereof, a pharmaceutically acceptable salt thereof, or solvate thereof. The compounds are useful in the prevention of or treatment for diseases relating to NAD(P)H....

20060089363 - Antibacterial agents: Compounds of formula (II) have antibacterial activity: wherein Q represents a radical of formula —N(OH)CH(═0) or formula —C(═O)NH(OH); R1 represents hydrogen, methyl or trifluoromethyl, or, except when Z is a radical of formula —N(OH)CH(═0), a hydroxy, halo or amino group; R2 represents a group R10-(V)n-(ALK)m- wherein R10 represents hydrogen, or...

20060089364 - Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents: m

20060089365 - Heterocyclic compounds useful as nurr-1 activators: The present invention relates to compounds of formula (I): wherein R1 is hydroxy, C1-4 alkoxy, amino, C1-4 alkyl-amino, di C1-4alkylamino, benzyloxy or C2-C7 alkanoyl, R2 is C1-4 alkyl, C1-4 alkoxy, C1-4 alkoxy C1-4alkoxy, CF3, halogen, C1-4alkylamino, di C1-4alkylamino, di C1-4 alkylamino C1-4 alkoxy or N—C1-4 alkoxy C1-4 alkyl-N—C1-4 alkylamino, N—C1-4...

20060089366 - New piperazine and piperidine compounds: The invention relates to a group of novel piperazine and piperidine derivatives of the formula wherein Y is hydrogen, halogen, alkyl (1-3C), or CN, CF3, OCF3, SCF3, alkoxy(1-3C), amino or mono- or dialkyl(1-3C) substituted amino or hydroxy, X is O, S, SO or SO2, ---Z represents -C, =C or -N,...

20060089367 - New indole or benzimidazole derivatives as cb1 inverse agonists: and pharmaceutically acceptable salts thereof, processes for making said compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compound and pharmaceutically acceptable salts thereof, and methods of using said compounds. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1...

20060089368 - Phenyl-piperazine derivatives as serotonin reuptake inhibitors: d

20060089369 - Inhibitors of glycogen synthase kinase 3: New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active...

20060089370 - Thieno-pyrimidine compounds having fungicidal activity: The present invention relates to thieno[2,3-d]-pyrimidine compounds having fungicidal activity....

20060089371 - Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist: in which the groups Q1-Q4, Ar, and R1-R7 are as defined in the specification and claims. These materials are useful as active ingredients of pharmaceutical preparations. The phenyl or heteroaryl amino alkanes of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment...

20060089372 - Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine: The invention concerns dihydroimi-dazo[5,1-a]-β-carboline compounds of general formula (1), wherein in particular, R1, R2, R2, Ra, R6 and K7, identical or different, independently of one another, represent a hydrogen, halogen atom, an alkyl, hydroxy, alkoxy, trihalogenoalkyl, alkylamino, dialkylamino, aryl, arylalkyl, carboxy, alkylcarbonyloxy, acyl, aryloxy or arylalkoxy group; R3 represents a...

20060089373 - High potency dopaminergic treatment of neurological impairment associated with brain injury: Methods and compositions are described for treating impaired neurological function, including altered state of consciousness disorders, in an individual who has sustained a brain injury comprising administering to the individual apomorphine. Methods and compositions are described for treating impaired neurological function, including altered state of consciousness disorders, in an individual...

20060089374 - Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease: Preferred embodiments of the present invention are related to novel therapeutic drugs and drug combinations, and associated methods, for treating and/or preventing complications in patients with diabetes, metabolic syndrome, and/or hypertension. More particularly, aspects of the present invention are related to the use of cicletanine as a monotherapy or in...

20060089375 - Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors: and wherein X is NR4R5 or OR5a. The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic...

20060089376 - Tenatoprazole salts and process of preparation thereof: wherein X is Li, Na, Ca, K or Mg and to a process for the preparation thereof which comprises oxidizing a compound of formula (2) and isolating the salt (Li, Na) by treatment with the alkali hydroxide or exchanging the sodium salt of tenatoprazole with Mg++ or Ca++ cation....

20060089377 - Tenatoprazole salts and process of preparation thereof: wherein X is Li, Na, Ca, K or Mg and to a process for the preparation thereof which comprises oxidizing a compound of formula (2) and isolating the salt (Li, Na) by treatment with the alkali hydroxide or exchanging the sodium salt of tenatoprazole with Mg++ or Ca++ cation....

20060089378 - Tetrahydro-pyridinyl pyrazole cannabinoid modulators: e

20060089379 - Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity: The present invention is directed to compounds of the formula I: I(wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the...

20060089380 - 8-hydroxy quinoline derivatives: The present invention relates to a method for the treatment, amelioration and/or prophylaxis of a neurological condition, in particular neurodegenerative disorders which comprises the administration of an effective amount of a compound of formula (I): to a subject in need thereof. The present invention also relates to a compound of...

20060089381 - Method of producing ethyl (3r, 5s, 6e)-7-[2 cyclopropyl-4-(fluorophenyl) quinoline-3-yl]-3, 5-dihydroxy-6-heptenoate: A method of producing Ethyl (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinoline-3-yl]-3,5-dihydroxy-6-heptenoate by means of liquid chromatography using a packing material comprising a carrier and, carried thereon, a polysaccharide derivative, wherein a part or all of the hydrogen atoms of hydroxyl and amino groups of the polysaccharide derivative are substituted with one or more substituents, such...

20060089382 - Substituted 3-cyanoquinolines as mek inhibitors: The invention concerns quinoline derivatives of Formula (I) wherein each of Z1, m, R1, n, R3, Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an...

20060089383 - Substituted piperidine compounds and methods of their use: Novel 3,4-disubstituted-4-aryl-piperidine compounds are disclosed. Pharmaceutical compositions containing the 3,4-disubstituted-4-aryl-piperidine compounds and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as antagonists of opioid receptors....

20060089384 - Ophthalmic compositions and methods of using the same: Ophthalmic compositions are provided that comprise or consist essentially of (a) ketotifen or a ketotifen salt, (b) a non-ionic tonicity agent, and (c) water. The concentration of ketotifen or the ketotifen salt is preferably from 0.01% to 0.05%. The non-ionic tonicity agent is preferably glycerol and the concentration of the...

20060089385 - Pharmaceutical compositions: Forms and formulations of VX-950 and uses thereof....

20060089386 - Novel process for substituted sulfoxides: The present invention relates to a process for preparing substituted sulfoxides either as a single enantiomer or in an enantiomerically enriched form. Thus, racemic omeprazole is reacted with (S)-camphorsulfonyl chloride to form a diastereomeric mixture and the diastereomers are separated by fractional crystallization, followed by deprotection to give esomeprazole....

20060089387 - Stabilized pharmaceutical composition comprising antidiabetic agent: This invention discloses a stabilized pharmaceutical composition comprising an antidiabetic agent and a stabilizer. The preferred stabilizers are selected from the group consisting of ascorbic acid, malic acid, maleic acid, tartaric acid, furmaric acid, citric acid, or combinations thereof. The antidiabetic agent is selected from the group consisting of [(±)5-[[2-(5-ethyl-2-pyridinyl)ethoxyl]phenyl]methyl]-thiazolidine-2,4-dione...

20060089388 - Use of parathyroid hormone-related protein (pthrp) in the diagnosis and treatment of chronic lung disease and other pathologies: This invention pertains to the discovery that Parathyroid Hormone-related Protein (PTHrP) can be detect and/or stage, and/or treat chronic lung diseases. In particular, it was discovered that PTHrP levels in broncho-alveolar lavage are indicative of lung “health” and “disease, and can be used to predict lung disease in patients at...

20060089389 - Combination: (i) an AT1-receptor antagonist or a pharmaceutically acceptable salt thereof; (ii) (a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof or (b) an insulin sensitizer or a pharmaceutically acceptable salt thereof; and, in case of a pharmaceutical composition, a pharmaceutically acceptable carrier....

20060089390 - 3-benzoyl-2,4,5-substituted pyridine derivatives or salts thereof and bactericides containing the same: To provide 3-benzoyl-2,4,5-substituted pyridine derivatives or their salts, fungicides containing them, and intermediates for producing them. By providing a group of compounds comprising specific 3-benzoyl-2,4,5-substituted pyridine derivatives or their salts, or fungicides containing them, which have so-called rainfastness, whereby they are capable of exhibiting excellent effects even when crops have...

20060089391 - Treatment of cancer in pediatric patients: Compositions comprising a cancer drug, a continuous oral dosing schedule with a drug which binds to the colchicine site of tubulin β-subunits, and methods of treating cancer in a pediatric patient using continuous dosing schedules are disclosed....

20060089392 - Ester derivatives and medicinal use thereof: or its pharmaceutically acceptable salt, or use of the same. The compound represented by the formula [1] or its pharmaceutically acceptable salt is useful as an agent for the treatment or prophylaxis of hyperlipidemia or the like, since it disappears very rapidly in the living body and has an excellent...

20060089393 - Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors: Compounds of formula (I) are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38....

20060089394 - Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators: A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof, wherein:...

20060089395 - Nf-kb activation inhibitors: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is {circle around (1)} a fused polycyclic heteroaryl group wherein the ring...

20060089396 - Halogenated benzamide derivatives: e

20060089397 - Synthetic diazonamides: The application discloses novel synthetic compounds, modeled after unique toxins extracted from the marine invertebrate Diazona angulata useful in the treatment abnormal cell mitosis. The application also discloses novel methods for synthesis of these compounds and methods of using these compounds....

20060089398 - Isoxazole carboxamide derivatives as ghrelin receptor modulators: or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus....

20060089399 - Pyrazolyl carboxanilides for controlling unwanted microorganisms:

20060089400 - Novel spiro ketone and carboxylic acid derivatives as specific inhibitors for (po3h2) ser/(po3h2)thr-pro-specific peptidyl-prolylcis/trans-isomerases: The invention provides new spiro and carboxylic acid derivatives, pharmaceutically compositions comprising them and their use for the preparation of pharmaceutical compositions....

20060089401 - Kinase inhibitors: The present invention provides a method for identifying inhibitors of protein kinases. Methods are also provided for inhibiting protein kinase activity. Specific non-peptide protein tyrosine kinase inhibitors are provided. The protein kinases produced using the method of the present invention may be used to treat a number of conditions in...

20060089402 - Compounds from antrodia camphorata and use thereof: The present invention relates to novel compounds from Antrodia camphorata and the use thereof....

20060089403 - Mono-acylated o-phenylendiamines derivatives: e

20060089404 - Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders: A class of chromane and chromene compounds having the structure shown below and pharmaceutically acceptable salts thereof are useful as therapeutic compounds, particularly in the treatment and control of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of conditions and sequelae...

20060089405 - Asymmetric synthesis of dihydrobenzofuran derivatives: c

20060089406 - Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases: The invention relates to a method of preventing and/or treating a chronic and/or an atopic skin disease by administering an inhibitor of fatty acid oxidation to a patient in a pharmacologically effective amount. Furthermore, the invention relates to the use of at least one inhibitor of fatty acid oxidation for...

20060089407 - Methods for making and using synergistic multifunctional compositions: The present invention is a synergistic palliative and/or therapeutic admixture for treating and/or medicating affected biological tissue in mammals. The admixture includes two or more multivalent metals and at least one polyfunctional organic ligand. The ligand is in the form of an alkaline earth salt. The molar ratio of metal...

20060089408 - Method of treating blepharospasm with a prostaglandin derivative: The present invention is a method of treating blepharospasm with a prostaglandin derivative, comprising the steps of (a) providing a predetermined amount of prostaglandin derivative; and (b) applying the prostaglandin derivative in a predetermined position. The prostaglandin derivative is preferably in the form of latanoprost wherein the chemical composition of...

20060089409 - Novel analogs of 3-o-acetyl-11-keto-ß-boswellic acid: These compounds exhibited 5-Lipoxigenase inhibitory properties and these compounds may be used in pharmaceutical compositions for therapeutic applications against a variety of inflammations and hypersensitivity-based human diseases including asthma, arthritis, bowel diseases such as ulcerative colitis and circulatory disorders such as shock and ischaemia. These compounds also inhibited the growth...

20060089410 - Combination of chemotherapeutic drugs for increasing antitumor activity: An oxyalkylene group containing histone deacetylase(s) inhibitor is used sequentially with another antineoplastic agent to increase antitumor activity in cells and mammals....

20060089411 - Treatment of stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin: Zeaxanthin, a natural carotenoid, can improve and increase the ability of enzyme inhibitors that can slow down certain enzymes that are contributing to toxic metabolite accumulation in people who suffer from Stargardt's disease or other lipofuscin disorders. Such enzyme inhibitors include retinoid analogs such as isotretinoin, commonly known by the...

20060089412 - Pharmaceutical composition for the treatment of non-alcoholic fatty liver disease: There is provided a method of preventing or treating non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis, which comprises administering a pharmaceutical composition comprising L-alanine as an active ingredient to a patient suffering from the disease. This pharmaceutical composition is safe and efficacious for prevention and/or therapeutic treatment of non-alcoholic fatty...

20060089413 - Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents: e

20060089414 - Generic probes for the detection of phosphorylated sequences: Generic probes that bind to phosphorylated amino acid residues are provided as well as methods employing the probes for screening for kinase inhibitory activity, kinase activity, and phosphatase activity. Methods for distinguishing serine/threonine kinase phosphorylation from tyrosine kinase phosphorylation are also provided....

20060089415 - Anti-infective agents and methods of use: n

20060084590 - Methods of and compounds for modulating the activity of bacterial fabg: Prokaryotic FAB G polypeptides and DNA (RNA) encoding such FAB G and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such FAB G for the treatment of infection, such as bacterial infections. Antagonists against such FAB G and their use as...

20060084592 - Peptide boronic acid inhibitors: o

20060084591 - Use of modulators of the signal transduction path using the protein kinase fyn for the treatment of tumorous diseases: The present invention describes the use of modulators of the signal transduction pathway via the protein kinase Fyn (e.g. Rho-kinase inhibitors or inhibitors of the protein kinase CSK) in the treatment of tumour diseases, especially in the therapy of neuroblastoma....

20060084593 - Anti-hiv composition, production method thereof and medicament: The present invention relates to an anti-HIV composition and to the method for producing it. The composition of the present invention comprises a polyanion and a molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein. The polyanion may be chosen, for example, from the...

20060084595 - Complex comprising ocif and polysaccharide: A complex comprising at least one substance selected from the group consisting of an osteoclastogenesis inhibitory factor, an analogue thereof and a variant thereof, which is bound to at least one substance selected from the group consisting of a polysaccharide and a polysaccharide derivative. The complex has a prolonged retention...

20060084594 - Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer: The invention discloses high levels of receptors for Clostridium perfringens enterotoxin (CPE) have been found in ovarian cancer and uterine cancer tissue samples. In addition, successful in vivo treatment of a mouse model of ovarian cancer with intraperitoneal injection of CPE is disclosed. High levels of Ep-CAM protein is also...

20060084596 - Growth factor binding molecules: Growth factor binding molecules having a plurality of peptide loops attached to a non-peptide organic scaffold, preferably having pseudo-six amino acid peptide loops with four amino acid sidechains. The growth factor binding molecules specifically bind various growth factors and are suitable for treating a subject having tumors or restinosis. In...

20060084599 - Compositions, methods and kits relating to notch signaling: The present invention relates to methods and compositions based on the modulation of Src-mediated cortactin phosphorylation. In particular, the invention features methods and compositions for modulating Src-mediated cortactin phosphorylation using Notch ligands to modulate Notch signaling....

20060084600 - Human homologues of fused gene: The invention relates to novel molecules, in particular nucleic acid sequences and the encoded polypeptides, which are the human homologues of the protein-serine/threonine kinase named Fused....

20060084603 - Igf-bp3-related methods for inhibiting tumor growth: The subject invention provides a method of inhibiting the proliferation of cells associated with a tumor in a subject which comprises administering to the subject between about 10 μg/kg and about 100 mg/kg of IGF-BP3, thereby inhibiting proliferation of the cells. The subject invention further provides a surgical method which...

20060084601 - Method for treating respiratory distress syndrome: The invention provides a method for treating infants, children or adults suffering from pulmonary distress caused by low or insufficient production of surfactant. It is particularly suitable for treating premature infants suffering from Respiratory Distress Syndrome. The method comprises administering a leptin compound to an individual with impaired surfactant production...

20060084602 - Platelet-derived growth factor compositions and methods of use thereof: A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and...

20060084605 - Stable pharmaceutical compositions: Pharmaceutical composition for parenteral administration comprising a glucagon-like peptide and human serum albumin or a variant thereof....

20060084604 - Transepithelial delivery of peptides with incretin hormone activities: Compositions and methods are disclosed for the treatment of diabetes and related diseases using peptides with incretin hormone activity. Preferably, the peptide with incretin hormone activity is GLP-1, exendin or an analog of GLP-1 or exendin. The peptides with incretin hormone activity are administered transepithelially using a transepithelial carrier peptide....

20060084598 - Use of alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia: The invention is based on the use of alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia, comprising the preparation of therapeutic concentrates of alpha-1 antitrypsin, in any form of administration tolerated by humans, the alpha-1 antitrypsin being obtained by purification of human plasma or being produced...

20060084597 - Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity: Use of a compound having 50% activity or more of the activity of gastric inhibitory polypeptide, GIP, when tested in the same assay under the same conditions, and/or the use of GIP, analogues and fragments thereof, for the manufacture of a pharmaceutical composition for prophylaxis and/or treatment of conditions caused...

20060084606 - Methods for reducing oxidative damage: The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three...

20060084607 - Purified amphiphilic peptide compositions and uses thereof: A plurality of amphiphilic peptide chains having alternating hydrophilic and hydrophobic amino acids, wherein the peptide contains at least 8 amino acids, are complementary and structurally compatible, and self-assemble into a beta-sheet macroscopic scaffold wherein peptide at least about 75% of the chains have the same sequence....

20060084608 - Binding polypeptides and methods based thereon: Binding polypeptides that specifically bind BLyS protein or BLyS-like polypeptides can be used in methods of the invention for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate function of BLyS or BLyS receptor, comprising BLyS binding polypeptides or fragments or...

20060084609 - Synthetic hla binding wt-1 peptide analogues and uses thereof: The present invention is directed to a synthetic peptide comprising a sequence of amino acids containing at least a segment that is an analogue of a native peptide that specifically binds to HLA A0201 or HLA A0301 molecules on a cell characteristic of a pathophysiologic state in a mammal. The...

20060084611 - Apoptotic compounds: The invention provides methods and compositions for enhancing apoptosis of pathogenic cells. The general method comprises the of contacting the cells with an effective amount of an AV peptoid, wherein the AV peptoid is a peptide comprising AX1, wherein X1 is V, I or L, or a peptide mimetic thereof,...

20060084610 - Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments: This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells. While the invention is not limited to any particular mechanism, the compounds of the invention appear to function at least in part by...

20060084612 - Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors: The present invention provides the combined use of acryloyl distamycin derivatives, in particular α-bromo- and α-chloro-acryloyl distamycin derivatives of formula (I), as set forth in the specification, and a protein kinase (serine/threonine and tyrosine kinases) inhibitor, in the treatment of tumors. Also provided is the use of the said combinations...

20060084613 - Inhibitors of the ice/ced-3 family of cysteine proteases: wherein A, B, R, R1, R1′ p and q are as defined herein. The invention is also directed to pharmaceutical compositions containing one or more of these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the...

20060084614 - Novel factor viia inhibiting compounds: e

20060084615 - Puerarin derivatives and their medical uses: The present invention provides acetylated derivatives of the compound puerarin that have enhanced bioavailability and are particularly suitable for oral administration. The present invention also teaches the use of medicaments containing acetylated derivatives of puerarin that are suitable for the treatment of myocardial ischemia and for modulating blood lipid levels,...

20060084616 - Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases, and uses thereof: wherein A is chosen from a nitrogen-, oxygen-, or sulfur-linked aryl, alkyl, cyclic, or heterocyclic group; both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen; and D is a primary alcohol, a...

20060084618 - Adiponectin promoter and use thereof: The present invention relates to a DNA having a promoter region containing regulatory sequences of human adiponectin gene, transformants transformed with the DNA, a screening method of a compound which can enhance the human adiponectin promoter activity, which the transformants are used, and the screening kit, and a screening method...

20060084622 - Angiogenic factor and use thereof in treating cardiovascular disease: The present invention relates to a novel VEGF protein product, and nucleic acid encoding the novel protein product, comprising exons 1-6 and 8 of the VEGF gene, and its use thereof in treating the cardiovascular system and its diseases through effects on anatomy, conduit function, and permeability. VEGF145 has been...

20060084621 - Compositions and methods for inhibiting expression of anti-apoptotic genes: The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an anti-apoptotic gene, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of an apoptotic gene, such as...

20060084623 - Dna vaccination for treatment of multiple sclerosis and insulin-dependent diabetes mellitus: A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive...

20060084617 - Methods for delivery of nucleic acids: This invention features methods and compositions for delivery of nucleic acids (e.g., DNA, RNA, PNA, and hybrids thereof) to cells. The nucleic acid delivery complexes of the invention permit biologically active nucleic acids to be delivered to cells and organisms in vitro and in vivo in a manner and form...

20060084619 - Novel neurotrophic factor protein and uses thereof: The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is...

20060084620 - Rna interference in respiratory epitheial cells: The present invention is directed to small interfering RNA molecules targeted against a gene of interest in respiratory epithelial cells, and methods of using these RNA molecules....

20060084624 - Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis b: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The...

20060084626 - Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist: Adenosine receptor agonists, particularly an agonist which binds to the A3 adenosine receptor, are used for induction of production or secretion of G-CSF within the body, prevention or treatment of toxic side effects of a drug or prevention or treatment of leukopenia, particularly drug-induced leukopenias; and inhibition of abnormal cell...

20060084625 - Use of a2a adenosine receptor agonists: Myocardial imaging methods that are accomplished by administering doses of a pharmaceutical composition including regadenoson—an adenosine A2A receptor agonist—to a human undergoing myocardial imaging in an amount sufficient to achieve at least a minimal increase in average coronary peak flow velocity....

20060084628 - Combination therapy for treating viral infections: A method of treating viral infections, particularly Hepatitis B (HBV) and Human Immunodeficiency Virus (HIV) infections, by administering Elvucitabine and a second active agent to a patient suffering viral infection is provided herein. The second active agent is, for example, an immunomodulatory compound, an anti-viral agent, or a combination comprising...

20060084627 - Synergistic interaction of abacavir and alovudine: A pharmaceutical preparation comprising a synergistic combination of abacavir and alovudine and a pharmaceutical carrier therefor. Use of abacavir and alovudine together for the treatment of multiresistant HIV, wherein the use comprises simultaneous, combined or sequential administration of alovudine and abacavir....

20060084631 - Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof: Methods and compositions for treating or preventing microbial infection in mammals with sulfated polysaccharides wherein the polysaccharides have a degree of sulfation effective to enable maximal interaction of constituent sulfate groups with the microbe which causes the infection and wherein the sulfated polysaccharide is not substantially endocytosed or degraded by...

20060084629 - Immune system activating formula composed of selected long chain polysaccharides from natural sources: A combination of two, specialized, high molecular weight-long chain fractions isolated from Aloe Vera and Maitake TD to stimulate immune system activity comprise long chain-high molecular weight polysaccharides which activate the body's natural immune response, triggering an increase in the production of macrophages, T-cells, B-cells, natural killer cells, cytokines and...

20060084630 - Method for synthesis of beta glucans: The invention provides a method for forming P-glucoside linkages in carbohydrate polymers, particularly synthetic glucan molecules, by attaching a protecting group to the C2 position of a glucoside donor. The protecting group of the invention stabilizes the dioxolenium ion and prevents orthoester formation to promote the β linkage and inhibit...

20060084632 - Topical gel formulation comprising organophosphate insecticide and its preparation thereof: The present invention provides a topical gel pharmaceutical formulation of insecticide suitable for treating an ectoparasite in a mammal, comprising: a) about 0.1-10% by weight of an insecticide; b) at least about 75% by weight of an organic solvent selected from the group consisting of a lower alkyl alcohol, a...

20060084634 - 7-pyrollyl tetracycline compounds and methods of use thereof: A compound of Formula (I):...

20060084633 - Formulations for treating or preventing mucositis: Mucositis is treated and/or prevented by administrating to a patient a formulation comprising a tetracycline that is poorly absorbed from the gastro-intestinal tract. The tetracycline may be in the form of a pharmaceutically acceptable salt or a base. The formulations may optionally also contain an antifungal agent to prevent fungal...

20060084635 - Aspirin and vitamin and/or trace element compositions for the amelioration and treatment of vascular disease: A medicament for the amelioration and treatment of vascular disease consisting of aspirin administered in combination with one or more of the vitamins including vitamin A, vitamin B6, vitamin C, vitamin E, and niacin. Alternative embodiments include the administration of aspirin in combination with one or more trace element including...

20060084636 - Methods of using fatty-acid esters of estrogens and serotonin reuptake inhibiting compounds for reducing the body weight of a mammal and compositions containing the same: Compositions and methods for reducing the body weight of a mammal are disclosed. The invention is directed to methods for reducing the body weight in a mammal comprising administering therapeutically effective amounts of a fatty-acid ester of an estrogen or estrogen derivative and a fatty-acid, and a serotonin reuptake-inhibiting compound....

20060084638 - Appetite-suppressing compositions and methods: The invention relates to appetite-suppressing compositions obtained from botanical sources. More specifically, the invention relates to appetite-suppressing compositions comprising an extract product of an Asclepias plant, methods of making an appetite-suppressing composition, and methods of suppressing an appetite....

20060084637 - Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same: Compositions and methods for reducing the body weight of a mammal are disclosed. The invention is directed to methods for reducing the body weight in a mammal comprising administering therapeutically effective amounts of a fatty-acid ester of an estrogen or estrogen derivative and a fatty-acid, and a thermogenic compound. Furthermore...

20060084639 - Compositions containing piperacillin and tazobactam useful for injection: The invention provides a pharmaceutical composition comprising piperacillin, tazobactam, an aminocarboxylic acid, and a buffer in a sodium lactate diluent. The invention further relates to a method of treating a bacterial infection and an LR condition in a human which comprises administering to said human an effective amount of a...

20060084641 - Il-8 receptor antagonists: This invention relates to the novel use of sulfonamide squaramides in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8)....

20060084640 - Vanilloid receptor ligands and their use in treatments: Therapeutic benzimidazoles and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory...

20060084642 - Substituted imidazol[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives: R3 is hydrogen, methyl or aryl; R is lower alkyl, cycloalkyl or aryl; and pharmaceutically acceptable acid addition salts thereof. Such compounds have a high affinity and selectivity for GABA A α5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders, anxiety,...

20060084643 - Piperazine substituted aryl benzodiazepines:

20060084644 - Novel pyridine compounds, process for their preparation and compositions containing them: The present invention provides new heterocyclic compounds, particularly substituted pyridines, methods and compositions for making and using these heterocyclic compounds, and methods for treating a variety of diseases and disease states, including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan....

20060084645 - Novel pyrimidine compounds, process for their preparation and compositions containing them: The present invention provides new heterocyclic compounds, particularly substituted pyrimidines, methods and compositions for making and using these heterocyclic compounds, and methods for treating a variety of diseases and disease states, including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan....

20060084646 - Method of preparing alkylated salicylamides via a dicarboxylate intermediate: The present invention relates to a method of preparing an alkylated salicylamide from a protected and activated salicylamide via a dicarboxylated salicylamide intermediate. The present invention also relates to dicarboxylic salicylamide delivery agent compounds for the delivery of active agents. Methods of administration are provided as well....

20060084647 - Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof: The invention relates to small molecules which function as inhibitors of anti-apoptotic Bcl-2 family member proteins (e.g., Bcl-2 and Bcl-xL). The invention also relates to the use of these compounds for inducing apoptotic cell death and sensitizing cells to the induction of apoptotic cell death....

20060084648 - Ethynyl derivatives as factor xa inhibitors: Novel compounds of the formula (I), in which R1, R2, R3, X and Y have the meaning indicated in Patent claim 1, are inhibitors ocoagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours....

20060084649 - Substituted alkyl amido piperidines: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective...

20060084650 - Kinase inhibitors: i

20060084652 - Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents:

20060084653 - Beta-sheet mimetics and composition and methods relating thereto: including pharmaceutically acceptable salts and stereoisomers thereof, wherein A, A′, B, X, Y, R2, R3, R4 and R5 are as defined herein. Such compounds have utility over a wide range of applications, including use as diagnostic and therapeutic agents. In particular, compounds of this invention, and pharmaceutical compositions containing such...

20060084651 - Chemical compounds: The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medcicaments. Such aminopyrazine derivatives are useful in the treatment of diseases associated with inappropriate tyrosine and/or serine/threonine kinase activity....

20060084656 - Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline: A composition for nasal administration comprising varenicline or its pharmaceutically acceptable salt and at least one excipient. The invention also provides a composition for buccal administration comprising varenicline or its pharmaceutically acceptable salt and at least one excipient to form a solid dosage form, wherein the solid dosage form disintegrates...

20060084654 - Imidazopyrazine tyrosine kinase inhibitors: c

20060084655 - Reverse-turn mimetics and method relating thereto: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed...

20060084657 - Piperazine derivative: wherein n is an integer of 1 to 8; R1 represents hydrogen or C1-10 alkyl; A represents CH or nitrogen; Ar1 represents phenyl or substituted phenyl; and Y represents a group represented by the formula Y1-Y2-Ar2 or Y3-Y4(Ar5)-Ar6 or a pharmaceutically acceptable salt of the derivative. The novel piperazine derivative...

20060084658 - Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound: In the formula, Ar indicates an optionally substituted 5- to 14-membered aromatic ring etc.; the ring A indicates any one ring selected from a piperazine, a homopiperazine, a piperidine and the like; the ring B indicates an optionally substituted C3-14 hydrocarbon ring etc.; E indicates a single bond, a group...

20060084659 - Augmentation of psychotherapy with cannabinoid reuptake inhibitors: Methods are provided for facilitating psychological extinction of a deleterious, high-anxiety response that is disproportionate to the threat offered by a given stimulus. An afflicted subject is treated with a cannabinoid reuptake inhibitor in conjunction with extinction training. The methods are relevant for treatment of anxiety disorders, including phobic disorders...

20060084660 - Calcium channel blockers comprising two benzhydril moieties: Certain piperazine compounds are described which are useful in altering calcium channel activity....

20060084661 - Il-8 receptor antagonists: This invention relates to the novel use of amide squaramides in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8)....

20060084662 - Phenyl-piperazine derivatives as serotonin reuptake inhibitors: i

20060084663 - Peroxisome proliferator activated receptor modulators: The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I: wherein: (a) R5 is selected from the group consisting of (C1-C6) alkyl, (C1-C6) alkenyl, substituted aryl(C0-C4)alkyl, substituted aryloxy(C0-C4)alkyl, substituted arylthio(C0-C4)alkyl, unsubstituted aryl(C0-C4)alkyl, unsubstituted aryloxy(C0-C4)alkyl, and unsubstituted arylthio(C0-C4)alkyl; (b) T1 is...

20060084665 - Quinolizinone compound and use thereof as hiv integrase inhibitor: wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing same as an active ingredient. The compound of the present invention has an HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS....

20060084664 - Substituted pyrido(1,2-a) pyrimidines and their use as nos inhibitors: e

20060084666 - Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient a therapeutically effective amount of an EGFR kinase inhibitor, combined with treating the patient simultaneously or sequentially with radiation therapy, with or without additional agents or treatments, such as other...

20060084667 - New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them: e

20060084668 - Isolated valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard: The present invention provides an isolated N-formyl valacyclovir, its preaparation and its use as a reference marker and/or reference standard....

20060084669 - Processes for the production of chinazoline alkaloids: e

20060084670 - Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer: The present invention relates to therapeutic associations for the treatment of cancer, comprising an effective amount of a camptothecin, or a camptothecin derivative, with an effective amount of an alkylating agent such as a platin derivative, and methods of using such therapeutic associations....

20060084671 - Process for the preparation of pure finasteride: e

20060084672 - Method for modification of y-secretase activity through inhibition of fkbp13: The present invention provides a method for modifying γ-secretase activity in a cell or in an organism by de-stabilizing presenilin through inhibition of Fkbp13. Inhibition of Fkbp13 de-stabilizes presenilin and prevents formation of a functional γ-secretase complex thus decreasing γ-secretase activity and concomitantly decreasing production of amyloid-β peptides. The invention...

20060084673 - 1,5-naphthyridine azolinone: 1,5-Naphthyridine azolinone derivatives are disclosed. These compounds are inhibitors of CDK1 and are useful as antiproliferative agents, such as anti-cancer agents....

20060084674 - Azaindole thiazolinones: Azaindole thiazolinone derivatives which demonstrate CDK1 and CDK2 antiproliferative activities and are useful as anti-cancer agents....

20060084675 - Combined treatment with artesunate and an epidermal growth factor receptor kinase inhibitor: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and artesunate combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy....

20060084676 - 3-aryl--3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same: The present invention relates to compounds of 3-aryl-3-methyl-quinoline-2,4-diones acting as a 5HT6 receptor antagonist, a preparation method thereof, and a pharmaceutical composition containing the same for treatment of the central nervous system disorders. The compounds of 3-aryl-3-methyl-quinoline-2,4-diones according to the present invention may be valuably used for treatment of a...

20060084678 - Methods for identifying and using marr family polypeptide binding compounds: Methods for identifying MarR family inhibiting compounds are described. The methods include the use of computer aided rational based drug design programs and three dimensional structures of MarR family polypeptides....

20060084677 - Quinoline derivatives as anti-inflammatory agents: wherein A is a CH2, CH(OH), C(O), C═NOR4, NR5, O, S, S(O), or S(O)2, and the other substituents are as defined in the specification; or prodrugs, individual isomers, mixtures of isomers, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their...

20060084679 - Quinoline derivatives as h3r inverse agonists: e

20060084680 - Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation: This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation....

20060084681 - Substituted pyrazoles, compositions containing such compounds and methods of use: The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus....

20060084682 - Thrombopoietin mimetics: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected...

20060084683 - Method for preventing the onset of asthma: The present invention relates to a method for preventing the onset of asthma which comprises administering to a patient a therapeutically effective amount of cetirizine, an individual optical isomer thereof or a pharmaceutically acceptable salt thereof....

20060084685 - Ophthalmological use of roflumilast for the treatment of diseases of the eye: A pharmaceutical preparation comprising roflumilast for treatment of a disease of the eye is described....

20060084684 - Topically applicable pharmaceutical preparation: A topical pharmaceutical preparation for administering a slightly soluble PDE 4 inhibitor that has a surprisingly good systemic bioavailability is described....

20060084686 - Methods of food intake management: Methods for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The...

20060084687 - Indole and benzimidazole derivatives: The present invention relates to new indole and benzimidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:...

20060084688 - Aromatic sulfone hydroxamic acid metalloprotease inhibitor: A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a...

20060084689 - Thiazole-amine compounds for the treatment of neurodegenerative disorders: wherein R1, R3, R4, R5, R6 and R7 are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods of treating disorders and diseases, for example, neurodegenerative and/or neurological disorders, e.g.